



Media Contacts: Chris Henneghan, IDT
610-269-2100, ext. 230
chenneghan@schubert.com

Gary Carter, Agilent
303-222-4949
gary.carter@agilent.com

TRADE NEWS: IDT and Agilent Technologies Sign Agreement to Offer Oligo Synthesis Encompassing Full Spectrum of Drug Development

Alliance Can Help Customers Reduce Time, Costs Traditionally Associated with Transition from Research to Clinical Development

CORALVILLE, Iowa, and SANTA CLARA, Calif., (May 8, 2007) – Integrated DNA Technologies Inc. (IDT) and Agilent Technologies (NYSE: A) have signed an agreement to harmonize the companies' chemistry, processes and analytical techniques, and to provide reciprocal referrals for synthetic oligonucleotides. This coordinated approach to serving customers will help end users reduce the time and costs typically spent when transitioning from the research stage to clinical development.

The agreement forms a complete developmental pathway for customers, including:

- screening and small-scale products produced at all IDT facilities;
- mid-scale products, such as products for animal studies, produced by the IDT Belgium facility; and
- large-scale quantities produced by Agilent's Nucleic Acid Solutions Division for use as active pharmaceutical ingredients (API) in clinical-trial and marketed-drug production; Agilent's oligos comply with the pharmaceutical GMP guidelines and ICH Q7.

“This agreement benefits both companies by broadening our customer base, but it ultimately benefits the life science research community,” said Trey Martin, chief operating officer at IDT. “We will now be able to offer researchers a bench-to-bedside oligonucleotide manufacturing package, featuring harmonized manufacturing methods from basic research scales through API manufacturing.”

“Our alliance will provide a competitive advantage to IDT and Agilent customers by significantly reducing the time and costs traditionally associated with the transition from research into clinical development,” said James Powell, general manager of Agilent’s Nucleic Acid Solutions Division. “In addition, by combining the expertise of Agilent and IDT, we will be able to offer best-in-class synthetic oligonucleotide manufacturing solutions to our customers.”

About Agilent in Nucleic Acids

Agilent, through its Nucleic Acid Solutions Division based in Boulder, Colo., is a leading provider of flexible therapeutic oligo development services and manufacturing solutions for the biotech and pharmaceutical industries. In addition to manufacturing cGMP therapeutic oligo materials, Agilent also offers an array of turn-key services, including development of analytical methods and processes, stability studies, quality control, and regulatory support.

About Agilent Technologies

Agilent Technologies (NYSE: A) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 19,000 employees serve customers in more than 110 countries. Agilent had net revenue of \$5.0 billion in fiscal 2006. Information about Agilent is available on the Web at www.agilent.com.

About IDT

Integrated DNA Technologies, Inc. is the largest supplier of custom nucleic acids in the United States, serving academic, government and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT’s primary business is the manufacturing of custom, synthetic DNA and RNA oligonucleotides. Founded in 1987 by Joseph Walder, M.D., Ph.D. (Northwestern University), IDT has achieved annual double-digit growth over the past 10 years. Today, IDT synthesizes and ships an average of 36,000 custom oligos per day to its more than 77,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa; San Diego, Calif.; and Leuven, Belgium.

###